Profile: Novavax, Inc. is a clinical-stage biotechnology company that develops novel vaccines to address a broad range of infectious diseases using advanced virus-like particle (VLP) technology. We produce VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. We also focus on particle-based vaccine approach to other viral diseases beyond influenza. We offer a randomized, double blind, placebo controlled clinical trial to evaluate the safety and immunogenicity of a seasonal influenza VLP vaccine in adults. We offer vaccines that are designed to protect against various circulating strains of Avian influenza as well as seasonal flu, respiratory syncytial virus and varicella zoster virus.